Llovet, Josep M.

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology

Hepatocellular Carcinoma Treatment and PrognosisStatistical Methods in Clinical Trials

Cited by 413

Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer

Malehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., et al. (2019) · Nature Medicine

Liver Disease Diagnosis and TreatmentLiver physiology and pathology

Cited by 398

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 391

Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis

Mazzaferro, V., Romito, R., Schiavo, M., Mariani, L., Camerini, T., Bhoori, S., Capussotti, L., Calise, F., Pellicci, R., Belli, G., et al. (2006) · Hepatology

Hepatocellular Carcinoma Treatment and PrognosisHepatitis C virus research

Cited by 367

Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment

Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology

Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and Treatment

Cited by 354

Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study

Kudo, M., Ren, Z., Guo, Y., Han, G., Lin, H., Zheng, J., Ogasawara, S., Kim, J. H., Zhao, H., Li, C., et al. (2025) · The Lancet

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 342

Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

Pinyol, R., Montal, R., Bassaganyas, L., Sia, D., Takayama, T., Chau, G.-Y., Mazzaferro, V., Roayaie, S., Lee, H. C., Kokudo, N., et al. (2019) · Gut

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 326

Medical therapies for hepatocellular carcinoma: a critical view of the evidence

Villanueva, A., Hernandez-Gea, V., & Llovet, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 314

Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib

Lachenmayer, A., Alsinet, C., Savic, R., Cabellos, L., Toffanin, S., Hoshida, Y., Villanueva, A., Minguez, B., Newell, P., Tsai, H.-W., et al. (2012) · Clinical Cancer Research

Wnt/β-catenin signaling in development and cancerHepatocellular Carcinoma Treatment and Prognosis

Cited by 306

Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification

Montironi, C., Castet, F., Haber, P. K., Pinyol, R., Torres-Martin, M., Torrens, L., Mesropian, A., Wang, H., Puigvehi, M., Maeda, M., et al. (2023) · Gut

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 253

Immune Exclusion-Wnt/CTNNB1 Class Predicts Resistance to Immunotherapies in HCC

Pinyol, R., Sia, D., & Llovet, J. M. (2019) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 249

Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)

Haber, P. K., Puigvehí, M., Castet, F., Lourdusamy, V., Montal, R., Tabrizian, P., Buckstein, M., Kim, E., Villanueva, A., Schwartz, M., et al. (2021) · Gastroenterology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 248

YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression

Fitamant, J., Kottakis, F., Benhamouche, S., Tian, H. S., Chuvin, N., Parachoniak, C. A., Nagle, J. M., Perera, R. M., Lapouge, M., Deshpande, V., et al. (2015) · Cell Reports

Hippo pathway signaling and YAP/TAZLiver physiology and pathology

Cited by 248

MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a

Toffanin, S., Hoshida, Y., Lachenmayer, A., Villanueva, A., Cabellos, L., Minguez, B., Savic, R., Ward, S. C., Thung, S., Chiang, D. Y., et al. (2011) · Gastroenterology

MicroRNA in disease regulationHepatocellular Carcinoma Treatment and Prognosis

Cited by 232

Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma: A Review

Cappuyns, S., Corbett, V., Yarchoan, M., Finn, R. S., & Llovet, J. M. (2024) · JAMA Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 167

Molecular Markers of Response to Anti-PD1 Therapy in Advanced Hepatocellular Carcinoma

Haber, P. K., Castet, F., Torres-Martin, M., Andreu-Oller, C., Puigvehí, M., Miho, M., Radu, P., Dufour, J.-F., Verslype, C., Zimpel, C., et al. (2023) · Gastroenterology

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 145

An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents

Moeini, A., Torrecilla, S., Tovar, V., Montironi, C., Andreu-Oller, C., Peix, J., Higuera, M., Pfister, D., Ramadori, P., Pinyol, R., et al. (2019) · Gastroenterology

Hepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathology

Cited by 92

Copy-Number Alteration Burden Differentially Impacts Immune Profiles and Molecular Features of Hepatocellular Carcinoma

Bassaganyas, L., Pinyol, R., Esteban-Fabró, R., Torrens, L., Torrecilla, S., Willoughby, C. E., Franch-Expósito, S., Vila-Casadesús, M., Salaverria, I., Montal, R., et al. (2020) · Clinical Cancer Research

Cancer Genomics and DiagnosticsCancer Immunotherapy and Biomarkers

Cited by 58

Exploring a new pathway for biomarker-based approval of immunotherapies

Llovet, J. M. (2023) · Nature Reviews Clinical Oncology

Cancer Immunotherapy and BiomarkersBiosimilars and Bioanalytical Methods

Cited by 16